Korean Journal of Family Practice

Table. 3.

Local and Systemic reactions reported within 10 days of 1 dose and the 2 dose SARS-CoV-2 vaccine (BNT162b2, Pfizer/BioNTech)

Dose 1 (N=139) Dose 2 (N=139)
Paina
Any 45 (32.4) 32 (23.0)
Mild 61 (43.9) 41 (29.5)
Moderate 32 (23.0) 63 (45.3)
Severe 1 (0.7) 3 (2.2)
Grade 4 0 (0) 0 (0)
Tendernessb
Any 55 (39.6) 36 (25.9)
Mild 39 (28.1) 39 (28.1)
Moderate 43 (30.9) 50 (36.0)
Severe 2 (1.4) 14 (10.1)
Grade 4 0 (0) 0 (0)
Erythema/rednessc
Any 131 (94.2) 118 (84.9)
Mild 7 (5.0) 14 (10.1)
Moderate 1 (0.7) 6 (4.3)
Severe 0 (0) 1 (0.7)
Grade 4 0 (0) 0 (0)
Induration/swellingc
Any 119 (85.6) 109 (78.4)
Mild 13 (9.4) 19 (13.7)
Moderate 6 (4.3) 11 (7.9)
Severe 0 (0) 0 (0)
Grade 4 0 (0) 0 (0)
Nausea/vomitingd
Any 124 (89.2) 109 (78.4)
Mild 11 (7.9) 17 (12.2)
Moderate 4 (2.9) 12 (8.6)
Severe 0 (0) 1 (0.7)
Grade 4 0 (0) 0 (0)
Diarrheae
Any 137 (98.6) 125 (89.9)
Mild 2 (1.4) 10 (7.2)
Moderate 0 (0) 2 (1.4)
Severe 0 (0) 2 (1.4)
Grade 4 0 (0) 0 (0)
Headachef
Any 103 (74.1) 77 (55.4)
Mild 18 (12.9) 16 (11.5)
Moderate 18 (12.9) 43 (30.9)
Severe 0 (0) 3 (2.2)
Grade 4 0 (0) 0 (0)
Fatigueg
Any 95 (68.3) 61 (43.9)
Mild 13 (9.4) 14 (10.1)
Moderate 28 (20.1) 43 (30.9)
Severe 3 (2.2) 21 (15.1)
Grade 4 0 (0) 0 (0)
Myalgiaf
Any 90 (64.7) 51 (36.7)
Mild 16 (11.5) 16 (11.5)
Moderate 28 (20.1) 43 (30.9)
Severe 5 (3.6) 29 (20.9)
Grade 4 0 (0) 0 (0)
Allergyf
Any 128 (92.1) 121 (87.1)
Mild 10 (7.2) 13 (9.4)
Moderate 0 (0) 2 (1.4)
Severe 1 (0.7) 2 (1.4)
Grade 4 0 (0) 1 (0.7)
Feverh
Any 130 (93.5) 104 (74.8)
Mild 8 (5.8) 27 (19.4)
Moderate 1 (0.7) 5 (3.6)
Severe 0 (0) 3 (2.2)
Grade 4 0 (0) 0 (0)
Other reactionsg
Any 124 (89.2) 109 (78.4)
Mild 7 (5.0) 5 (3.6)
Moderate 5 (3.6) 8 (5.8)
Severe 3 (2.2) 16 (11.5)
Grade 4 0 (0) 1 (0.7)

Values are presented as number (%).

aMild, does not interfere with activity; moderate, requires a Tylenol-type drug because it interferes with daily life; severe, requires a strong pain reliever (SEVER) because it is very difficult to daily life; grade 4, emergency room visit or hospitalization. bMild, does not interfere with activity; moderate, interferes with activity; severe, prevents daily activity; grade 4, emergency room visit or hospitalization. cMild, 2.0–5.0 cm in diameter; moderate, >5.0–10.0 cm in diameter; severe, >10.0 cm in diameter; grade 4, necrosis or exfoliative dermatitis for redness, and necrosis for swelling. Data were collected with the use of Self-check questionnaire for 10 days after 2nd vaccination. dMild, 1–2 times in 24 h; moderate, >2 times in 24 h; severe, requires intravenous hydration; grade 4 for all events: emergency room visit or hospitalization. eMild, 2–3 loose stools in 24 h; moderate, 4–5 loose stools in 24 h; severe: 6 or more loose stools in 24 h; grade 4 for all events: emergency room visit or hospitalization. fMild, does not interfere with activity; moderate, requires a Tylenol-type drug because it interferes with daily life; severe, requires a strong pain reliever (SEVER) because it is very difficult to daily life; grade 4, emergency room visit or hospitalization. gMild, does not interfere with activity; moderate, some interference with activity; severe, prevents daily activity; grade 4, emergency room visit or hospitalization; grade 4 for all events: emergency room visit or hospitalization; and fever (hMild, 38.0°C–38.4°C moderate, 38.5°C–38.9°C; severe, 39.0°C–40.0°C; grade 4, >40.0°C). Data were collected with the use of Self-check questionnaire for 10 days after 2 dose Pfizer-BioNTech COVID-19 vaccination.

Korean J Fam Pract 2021;11:357~364 https://doi.org/10.21215/kjfp.2021.11.5.357
© KJFP